Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Items 701–800 of 1,000
Pilgrim, A. A., Jonus, H. C., Ho, A. K. S., Cole, A. C., Shim, J., & Goldsmith, K. C. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2240678 · Cited by 27
“dinutuximab) significantly improved survival for newly diagnosed patients with high-risk disease.(22,23) Anti-GD2 antibodies have also been combined with cytotoxic chemotherapy (“chemoimmunotherapy”), which demonstrated impressive response rates for”
BackgroundInvolvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy
Pistoia, V., & Pezzolo, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/3142365 · Cited by 23
“A therapeutic protocol based upon the combination of anti-GD2 antibody, GM-CSF, IL-2, and isotretinoin has shown great efficacy in a cohort of high risk NB patients, with 2-year event-free survival of 66% and overall survival of 86% [20].”
Racotumomab for treating lung cancer and pediatric refractory malignancies
Gabri, M. R., Cacciavillano, W., Chantada, G. L., & Alonso, D. F. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1157579 · Cited by 27
Nguyen, T. H., Koneru, B., Wei, S., Chen, W. H., Makena, M. R., Urias, E., Kang, M. H., & Reynolds, C. P. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0385 · Cited by 24
“Despite intensive treatment with surgery, chemotherapy, myeloablative chemotherapy, and radiotherapy, followed by maintenance therapy with 13-cis-retinoic acid and anti-GD2 antibody þ cytokines, the 5-year overall survival rate for patients with high-risk neuroblastoma is still approximately 50% (1, 2).”
BackgroundSelf-citationChuang, H., Lin, H., Liao, P.-L., Huang, C., Lin, L., Hsu, W., & Chuang, J. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0356-0 · Cited by 23
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma
Marx, S., Wilken, F., Wagner, I., Marx, M., Troschke‐Meurer, S., Zumpe, M., Bien-Moeller, S., Weidemeier, M. E., Baldauf, J., Fleck, S. K., et al. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03470-3 · Cited by 23
Tucker, E. R., George, S. L., Angelini, P., Bruna, A., & Chesler, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040248 · Cited by 25
“Progress in the treatment of high-risk neuroblastoma was accelerated in recent years through the addition of immunotherapy to target minimal residual disease [80].”
BackgroundShukla, A., Cano‐Mejia, J., Andricovich, J., Burga, R. A., Sweeney, E. E., & Fernandes, R. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100021 · Cited by 25
Zirngibl, F., Ivasko, S. M., Grunewald, L., Klaus, A., Schwiebert, S., Ruf, P., Lindhofer, H., Astrahantseff, K., Andersch, L., Schulte, J. H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002923 · Cited by 24
Görges, M., West, N., Deyell, R. J., Winton, P., Cheung, W., & LAUDER, G. R. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25197 · Cited by 23
“One patient (16%) experienced grade 3 hypotension during one treatment day, which is comparable to a previous study reporting a prevalence of 18% [5].”
BackgroundResultInfluentialEnhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG
Alderson, K. L., Luangrath, M. A., Elsenheimer, M. M., Gillies, S. D., Navid, F., Rakhmilevich, A. L., & Sondel, P. M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1372-8 · Cited by 23
“Clinical data from our laboratory have recently suggested that myeloid cells may play a role in the therapeutic effect of mAb in neuroblastoma patients [20, 44, 45].”
Self-citationSung, K. W., Park, J. E., Chueh, H. W., Lee, S. H., Yoo, K. H., Koo, H. H., Kim, J. Y., & Cho, E. J. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23035 · Cited by 23
Therapeutic Antibodies to Ganglioside GD2 Evolved from Highly Selective Germline Antibodies
Sterner, E., Peach, M. L., Nicklaus, M. C., & Gildersleeve, J. C. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.050 · Cited by 26
Suh, J. K., Koh, K., Min, S. Y., Kim, Y. S., Kim, H., Im, H. J., Namgoong, J., Kim, D. Y., Ahn, S. D., Lee, J. J., et al. (2020) · Pediatric Transplantation · doi:10.1111/petr.13658 · Cited by 22
“Six patients experienced disease relapse at a median of 10 months (range 1-19) after the second HDCT and a median of 23 months (14-34) after diagnosis.”
BackgroundWieczorek, A., Śladowska, K., & Lode, H. N. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01155-3 · Cited by 22
“Anti-GD2 monoclonal antibodies are the standard of care for maintenance treatment in the first-line setting for patients with HR-NB [4, 5]; however, there is no standard of care for maintenance in the R/R setting [6, 8, 18].”
Investigational drugs in phase II clinical trials for the treatment of neuroblastoma
Amoroso, L., Haupt, R., Garaventa, A., & Ponzoni, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1380625 · Cited by 24
“demonstrated that the addition of dinutuximab (antibody directed against the GD2 ganglioside, a cell-surface marker expressed by NB tumor cells) with cytokines granulocyte-macrophage colony-stimulating factor (GMCSF) and interleukin-2 (IL-2) to standard isotretinoin maintenance therapy significantly improved short-ter…”
BackgroundInfluentialReal World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India
Radhakrishnan, V. S., Raja, A., Dhanushkodi, M., Ganesan, T. S., Selvaluxmy, G., & Sagar, T. G. (2019) · The Indian Journal of Pediatrics · doi:10.1007/s12098-018-2834-6 · Cited by 23
Oral drug delivery for immunoengineering
Le, T. C., Aguilar, B., Mangal, J. L., & Acharya, A. P. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10243 · Cited by 22
Aiken, T. J., Erbe, A. K., Zebertavage, L., Komjathy, D., Feils, A. S., Rodriguez, M., Stuckwisch, A. M., Gillies, S. D., Morris, Z. S., Birstler, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004834 · Cited by 23
Self-citationHung, J., Chen, I., Ueng, S., Huang, C., Chen, S., Chen, M.-Y., Lin, Y., Lin, C., Campbell, M. J., Rugo, H. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004312 · Cited by 22
Self-citationPaolo, D. D., Yang, D., Pastorino, F., Emionite, L., Cilli, M., Daga, A., Destafanis, E., Fiore, A. D., Piaggio, F., Brignole, C., et al. (2015) · Oncotarget · doi:10.18632/oncoscience.4342 · Cited by 24
Shibina, A., Seidel, D., Somanchi, S. S., Lee, D. A., Stermann, A., Maurer, B. J., Lode, H. N., Reynolds, C. P., & Huebener, N. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0958-0 · Cited by 23
Self-citationShah, N., Wang, J., Selich‐Anderson, J., Graham, G. T., Siddiqui, H., Li, X., Khan, J. I., & Toretsky, J. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1486 · Cited by 23
“Despite intensive treatment and improved responses with the introduction of immunotherapy (3), up to 40% of high-risk patient tumors progress during induction chemotherapy (4) and 5-year disease-free survival remains <50% (5).”
BackgroundMakin, G. (2014) · Paediatrics and Child Health · doi:10.1016/j.paed.2013.09.002 · Cited by 22
αβ T-cell receptor bias in disease and therapy (Review)
WANG, C.-Y., Yu, P., He, X., FANG, Y.-X., Cheng, W., & Jing, Z. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3492 · Cited by 22
Chen, N. E., Maldonado, N. V., Khankaldyyan, V., Shimada, H., Song, M. M., Maurer, B. J., & Reynolds, C. P. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0156 · Cited by 22
“Moreover, well-tolerated agents that demonstrate clinical activity against recurrent neuroblastoma may be used to further improve outcome by employing them in post-consolidation maintenance therapy (2, 4, 20) Both 4-HPR/ LXS and ABT-751 are well-tolerated, orally available drugs with differing mechanisms of action and…”
BackgroundMethodSelf-citationSpinal Canal Involvement in Neuroblastoma
Trahair, T. N., Sorrentino, S., Russell, S., Sampaio, H. A., Selek, L., Plantaz, D., Freyçon, C., Simon, T., Kraal, K. C. J. M., Popovic, M. B., et al. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.05.051 · Cited by 24
CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells
Chaudhari, N., Talwar, P., d’Hellencourt, C. L., & Ravanan, P. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00310 · Cited by 23
“Consolidation therapies like differentiation therapy, antibody therapy, and immunotherapy are prescribed for treating minimal residual disease (Matthay et al., 1999; Yu et al., 2010; Lopci, 2015).”
BackgroundSiebert, N., Troschke‐Meurer, S., Marx, M., Zumpe, M., Ehlert, K., Gray, J. C., Garaventa, A., Manzitti, C., Ash, S., Klingebiel, T., et al. (2018) · Cancers · doi:10.3390/cancers10100387 · Cited by 22
“18 produced in SP2/0 cells [2].”
InfluentialDelgado, J. A., Jaramillo, D., Chauvin, N. A., Guo, M., Stratton, M. S., Sweeney, H. E., Barrera, C. A., & Mostoufi‐Moab, S. (2019) · Pediatric Radiology · doi:10.1007/s00247-019-04409-1 · Cited by 22
Mora, J., Castañeda, A., Flores, M. A., Santa‐María, V., Garraus, M., Gorostegui, M., Simão, M., Pérez‐Jaume, S., & Mañé, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.575009 · Cited by 23
“On the other hand, the impact of anti-GD2 immunotherapy on OS is significant and recurrent in all reported studies (Yu et al., 2010; Ladenstein et al., 2018; Ladenstein et al., 2020; Kushner et al., 2016).”
BackgroundMethodResultInfluentialTandem stem cell rescue as consolidation therapy for high‐risk neuroblastoma
Qayed, M. D., Chiang, K., Ricketts, R. R., Alazraki, A. L., Tahvildari, A. M., Haight, A. E., George, B., Esiashvili, N., & Katzenstein, H. M. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23155 · Cited by 25
“Immunotherapy with anti-GD2 monoclonal antibody in COG ANBL0032 has resulted in a 20% increase in survival with 2-year EFS of 66% [11,12].”
BackgroundInfluentialMarachelian, A., Desai, A. V., Balis, F. M., Katzenstein, H. M., Qayed, M. D., Armstrong, M. B., Neville, K. A., Cohn, S. L., Bush, M., Gunawan, R., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2955-9 · Cited by 22
“02) at 2 years on the immunotherapy arm [12].”
InfluentialSelf-citationErbe, A. K., Wang, W., Reville, P. K., Carmichael, L. L., Kim, K., Mendonça, E. A., Song, Y., Hank, J. A., London, W. B., Naranjo, A. H., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00675 · Cited by 22
“isoforms of HLA-Bw4: (1) HLA-B-Bw4 with threonine at amino acid 80 (B-Bw4-T80);”
BackgroundMethodInfluentialSelf-citationSpunt, S. L., Vargas, S. O., Coffin, C. M., Skapek, S. X., Parham, D. M., Darling, J., Hawkins, D. S., & Keller, C. (2011) · Cancer · doi:10.1002/cncr.26620 · Cited by 23
Targeted treatment of solid tumors in pediatric precision oncology
Bertacca, I., Pegoraro, F., Tondo, A., & Favre, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176790 · Cited by 22
“Target Drug Indication Reference GD2 Dinutuximab Naxitamab CAR-T Neuroblastoma Ewing sarcoma Glioma (9, 37) NCT02765243 NCT04196413 NCT04099797 CD171 CAR-T Neuroblastoma NCT02311621 PD-1 Nivolumab Camrelizumab CAR-T Neuroblastoma Renal cell carcinoma Osteosarcoma Soft-tissue sarcomas ATRT (38, 39) NCT04433221 NCT05407…”
BackgroundInfluentialBelgiovine, C., Mebelli, K., Raffaele, A., Cicco, M. D., Rotella, J., Pedrazzoli, P., Zecca, M., Riccipetitoni, G., & Comoli, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063225 · Cited by 25
“…of care in the first-line treatment of children with high-risk neuroblastoma after induction chemotherapy and autologous hematopoietic stem cell transplantation, and they are used also to treat relapsed or refractory neuroblastoma patients with or without minimal residual disease positivity [133].”
BackgroundMethodOcular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A
Tse, B. C., Navid, F., Billups, C. A., O'Donnell, T., & Hoehn, M. E. (2015) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2014.11.005 · Cited by 21
Elborai, Y. E. S., Hafez, H., Moussa, E. A. H., Hammad, M., Hussein, H., Lehmann, L., & Elhaddad, A. (2015) · Pediatric Transplantation · doi:10.1111/petr.12638 · Cited by 21
Orbital Metastasis Is Associated With Decreased Survival in Stage M Neuroblastoma
Harreld, J. H., Bratton, E. M., Federico, S. M., Li, X., Grover, W., Li, Y., Kerr, N. C., Wilson, M. W., & Hoehn, M. E. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25847 · Cited by 21
Synthesis and Binding of Mannose‐Specific Synthetic Carbohydrate Receptors
Bravo, M. F., Palanichamy, K., Shlain, M. A., Schiro, F., Naeem, Y., Marianski, M., & Braunschweig, A. B. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000481 · Cited by 21
Belounis, A., Ayoub, M., Cordeiro, P., Lemieux, W., Teira, P., Haddad, É., Herblot, S., & Duval, M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02581-0 · Cited by 23
Immunotherapy approaches targeting neuroblastoma
Nguyen, R., & Thiele, C. J. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000982 · Cited by 22
“clinical scenario to testmonoclonal antibodytherapy and cytokines [21].”
BackgroundMethodResultInfluentialSeitz, C. M., Flaadt, T., Mezger, M., Lang, A.-M., Michaelis, S. U., Katz, M., Syring, D., Joechner, A., Rabsteyn, A., Siebert, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690467 · Cited by 22
“The long-term consolidation treatment with dinutuximab was dosed in the range of regimens with proven objective response rates in high-risk and refractory neuroblastoma patients (9, 32) who continuously showed relevant dinutuximab serum levels over”
BackgroundNeuroblastoma—Telomere maintenance, deregulated signaling transduction and beyond
Stainczyk, S. A., & Westermann, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33839 · Cited by 21
“colony-stimulating factor and 13-cis-retinoic acid compared to 13-cisretinoic acid alone significantly improved the survival of high-risk neuroblastoma patients after stem cell transplantation.(119,120)”
BackgroundMarket access to new anticancer medicines for children and adolescents with cancer in Europe
Schoot, R. A., Otth, M., Frederix, G., Leufkens, H. G. M., & Vassal, G. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.034 · Cited by 21
Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells
Pajtler, K. W., Rebmann, V., Lindemann, M., Schulte, J. H., Schulte, S., Stauder, M., Leuschner, I., Schmid, K., Koehl, U., Schramm, A. R., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28096 · Cited by 21
“gens, such as the GD2 disialoganglioside, has been tested in advanced clinical trials with promising results.(7) Despite the need to better understand tumor-immune response mecha-”
BackgroundBaiu, D. C., Artz, N. S., McElreath, M. R., Menapace, B. D., Hernando, D., Reeder, S. B., Grüttner, C., & Otto, M. (2015) · Nanomedicine · doi:10.2217/nnm.15.138 · Cited by 22
Treatment of high-risk neuroblastoma with anti-GD2 antibodies
Castel, V., Segura, V., & Cañete, A. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0600-y · Cited by 24
Mayes, P. A., Degenhardt, Y., Wood, A., Toporovskya, Y., Diskin, S. J., Haglund, E. A., Moy, C. H., Wooster, R. F., & Maris, J. M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27781 · Cited by 23
“The treatment of patients with advanced neuroblastoma exemplifies this approach, as patients receive an intensive induction regimen which includes cytotoxic chemotherapies as well as a combination of biologic therapies including 13-cis-retinoic acid, an anti-GD2 monoclonal antibody, granulocyte-macrophage colony-stimu…”
BackgroundSelf-citationSaarinen‐Pihkala, U. M., Hovi, L., Koivusalo, A., Jahnukainen, K., Karikoski, R., Sariola, H. V., & Wikström, S. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24173 · Cited by 22
“HDtx, high-dose therapy; DOD, died of underlying disease; TBI, total body irradiation; TBI#, head not included; TBI test, testicular shielding; L-PAM, melphalan; preop, preoperative; PEM-TBI, cisplatin þ etoposide þ melphalan þ TBI; Eto-Carbo-TT, etoposide þ carboplatin þ thiotepa; Topo, topotecan; PPEM, 2 doses of ci…”
BackgroundMethodInfluentialMiyake, M., Hori, S., Ohnishi, S., Toritsuka, M., Fujii, T., Shimizu, T., Owari, T., Morizawa, Y., Gotoh, D., Itami, Y., et al. (2019) · Cancer Science · doi:10.1111/cas.14158 · Cited by 21
Wieczorek, A., Żebrowska, U., Ussowicz, M., Sokół, A., Stypińska, M., Dembowska-Baginska, B. M., Pawińska-Wąsikowska, K., & Balwierz, W. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165252 · Cited by 20
“The first randomized trial demonstrating improved survival with anti-GD2 antibodies compared with standard therapy in patients with HR-NB was the ANBL0032 study of the Children’s Oncology Group (COG) [2].”
BackgroundCopper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma
Rouaen, J. R. C., Salerno, A., Shai-Hee, T., Murray, J. E., Castrogiovanni, G., McHenry, C., Jue, T. R., Pham, V., Bell, J. L., Poursani, E. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54689-x · Cited by 23
Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma
Lin, Z., Wu, Z., & Luo, W. (2021) · Cancers · doi:10.3390/cancers13174469 · Cited by 21
“GD2 is often used in treating neuroblastomas and has achieved encouraging results [64].”
BackgroundTargeting tumor microenvironment and metastasis in children with solid tumors
Wessel, K. M., & Kaplan, R. N. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001082 · Cited by 21
Fox, E., Mossé, Y. P., Meany, H. J., Gurney, J. G., Khanna, G., Jackson, H. A., Gordon, G., Shusterman, S., Park, J. R., Cohn, S. L., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24900 · Cited by 20
Self-citationTumor‐targeted and immune‐targeted monoclonal antibodies: Going from passive to active immunotherapy
Marabelle, A., & Gray, J. C. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25508 · Cited by 20
“Recently, it has been demonstrated in a Phase III randomized trial that a mAb targeting the ganglioside GD2 could improve the survival of children with high-risk neuroblastoma [2].”
BackgroundFeraco, A. M., Dussel, V., Orellana, L., Kang, T. I., Geyer, J. R., Rosenberg, A. R., Feudtner, C., & Wolfe, J. (2017) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2016.11.013 · Cited by 22
Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications
Armideo, E., Callahan, C. A., & Madonia, L. (2017) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2017.8.1.4 · Cited by 20
“Hypersensitivity reactions can be seen during any dinutuximab-containing cycle but were noted to be more frequent during IL-2–containing courses (courses 2 and 4; Yu et al., 2010).”
InfluentialDuvalyan, A., Cha, A., Goodarzian, F., Arkader, A., Villablanca, J. G., & Marachelian, A. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28236 · Cited by 23
Self-citationDevelopment of differentiation modulators and targeted agents for treating neuroblastoma
Jin, Z., Lu, Y., Wu, Y., Che, J., & Dong, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112818 · Cited by 22
Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3
Li, N., Spetz, M. R., Li, D., & Ho, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107892 · Cited by 22
Socioeconomic disparities in survival after high‐risk neuroblastoma treatment with modern therapy
Zheng, D. J., Li, A., Ma, C., Ribeiro, K. B., Diller, L., Bona, K. O., & Marron, J. M. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29127 · Cited by 20
“Our specific aims for this study were to (1) describe differences in OS among patients with high-risk neuroblastoma by individual- and county-level SES characteristics; and (2) investigate whether changes in OS over time in patients with high-risk neuroblastoma differ by these characteristics.”
MethodShen, C. J., & Terezakis, S. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679701 · Cited by 22
Cardenas, F. I., Mauguen, A., Cheung, I. Y., Kramer, K., Kushner, B. H., Ragupathi, G., Cheung, N. V., & Modak, S. I. (2021) · Cancers · doi:10.3390/cancers13246265 · Cited by 20
Najem, S., Langemann, D., Appl, B., Trochimiuk, M., Hundsdoerfer, P., Reinshagen, K., & Eschenburg, G. (2016) · Oncotarget · doi:10.18632/oncotarget.12055 · Cited by 23
“Prognosis for stage 4 high-risk neuroblastoma is still poor albeit significant improvements in therapy were established that supplement high-dose chemotherapy and irradiation with innovative measures as immunotherapy [3].”
BackgroundLiu, L., Li, Y., Xiong, X., Qi, K., Zhang, C., Fang, J., & Guo, H. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3756 · Cited by 20
Faraj, S., Bahri, M., Fougeray, S., Roz, A. E., Fleurence, J., Véziers, J., Leclair, M., Thébaud, E., Paris, F., & Birklé, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373232 · Cited by 20
“For example, the anti-GD2 therapeutic antibody dinutuximab often causes dose-limiting side effects, such as severe pain during and after the infusion.(8) This on-target”
BackgroundCasey, D. L., Kushner, B. H., Cheung, N. V., Modak, S. I., Basu, E. M., Roberts, S. S., LaQuaglia, M. P., & Wolden, S. L. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.02.004 · Cited by 20
Troschke‐Meurer, S., Siebert, N., Marx, M., Zumpe, M., Ehlert, K., Mutschlechner, O., Loibner, H., Ladenstein, R. L., & Lode, H. N. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1661194 · Cited by 21
“18-mediated efficacy in patients.(2) Indeed, after the first 5 d of IL-2 administration, we found an about 3-fold increase of NK cell counts.”
BackgroundInfluentialJazmati, D., Butzer, S., Hero, B., Khalil, D. A., Merta, J., Bäumer, C., Plum, G., Fuchs, J., Koerber, F., Steinmeier, T., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.617506 · Cited by 24
Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma
Mao, C., Poimenidou, M., & Craig, B. T. (2024) · Cancers · doi:10.3390/cancers16162865 · Cited by 22
“Despite the favorable expression pattern of GD2 on NBL tumor cells, neuropathic pain remains a major problem and is the primary dose-limiting toxicity associated with this therapeutic approach [107].”
BackgroundReprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells
Giudice, A. M., Roth, S. L., Matlaga, S., Cresswell-Clay, E., Mishra, P., Schürch, P. M., Boateng-Antwi, K. A. M., Samanta, M., Pascual‐Pasto, G., Zecchino, V. P., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.025 · Cited by 21
Precision sniper for solid tumors: CAR-NK cell therapy
Li, S., Jing, J., Chen, Y., Chi, E., Wang, B., Xie, Z., Yang, W., Shen, H., & Pan, J. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04106-z · Cited by 25
“However, challenges remain in ensuring persistence and overcoming immunosuppressive microenvironments.”
Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review
Mora, J. (2022) · Cancers · doi:10.3390/cancers14112572 · Cited by 23
“The only randomized controlled trial involved HR-NB patients who received either antiGD2 mAb dinutuximab-containing immunotherapy or cis-RA after ASCT (ANBL0032) [60].”
BackgroundSpasov, N., Dombrowski, F., Lode, H. N., Spasova, M., Ivanova, L. R., Mumdjiev, I., Burnusuzov, H. A., & Siebert, N. (2022) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002488 · Cited by 19
Bellary, A., Nowak, C. M., Iwanicki, I. J., Flores-Guzmán, F., Wu, L. L., Kandel, J. J., Laetsch, T. W., Bleris, L. G., Hernandez, S. L., & Sirsi, S. R. (2023) · Theranostics · doi:10.7150/thno.81700 · Cited by 21
“Current standard-of-care for high-risk disease includes surgical resection, intensive chemoradiotherapy, stem cell transplantation, and immunotherapy [2,3].”
The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches
Polychronopoulos, P. A., Bedoya-Reina, O. C., & Johnsen, J. I. (2024) · Cancers · doi:10.3390/cancers16101863 · Cited by 21
“Maintenance therapy includes isotretinoin (13-cis-retinoic acid), which induces differentiation of neuroblastoma tumor cells, together with immunotherapy, such as anti-disialoganglioside (anti-GD2) antibodies and cytokines (GM-CSF and IL-2) [84,85].”
BackgroundNK Cell-based Immunotherapies in Pediatric Oncology
McDowell, K. A., Hank, J. A., DeSantes, K. B., Capitini, C. M., Otto, M., & Sondel, P. M. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000303 · Cited by 21
Self-citationCellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy
Huang, M. A., Krishnadas, D. K., & Lucas, K. G. (2015) · Journal of Immunology Research · doi:10.1155/2015/675269 · Cited by 19
Stem cell state and the epithelial-to-mesenchymal transition: Implications for cancer therapy
Donnenberg, V. S., & Donnenberg, A. D. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.486 · Cited by 19
“Monoclonal antibodies provide an alternative approach to targeting the gangliosides that characterize EMT and many neuroendocrine tumors.(132) The monoclonal antibody ch14.”
BackgroundAntitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering
Xu, H., Guo, H.-F., Cheung, I. Y., & Cheung, N. V. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0221 · Cited by 20
“Anti-GD2 antibody immunotherapy has proven efficacy (18, 19).”
BackgroundBartholomew, J., Washington, T., Bergeron, S., Nielson, D., Saggio, J., & Quirk, L. (2016) · Journal of Pediatric Oncology Nursing · doi:10.1177/1043454216659448 · Cited by 20
Toro-Salazar, O. H., Lee, J. H., Zellars, K. N., Perreault, P. E., Mason, K. C., Wang, Z., Hor, K. N., Gillan, E., Zeiss, C. J., Gatti, D. M., et al. (2018) · Cardio-Oncology · doi:10.1186/s40959-018-0030-5 · Cited by 20
Adoptive Cell Therapy in Treating Pediatric Solid Tumors
Tesfaye, M., & Savoldo, B. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0715-9 · Cited by 21
Wang, H., Yang, J., Pan, H., Tai, M.-C., Maher, M. H., Jia, R., Ge, S., & Lu, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s228532 · Cited by 20
Tumor-Associated Antigens (TAAs) for the Serological Diagnosis of Osteosarcoma
Li, J., Qin, B., Huang, M., Ma, Y., Li, D., Li, W., & Guo, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665106 · Cited by 22
“The GD2 ganglioside was found overexpressed in OS (48) and later, some groups demonstrated that the therapy anti-GD2 antibody can improve the survival rate of high-risk neuroblastoma (49).”
BackgroundHigh-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
Cai, J., Jacob, S., Kurupi, R., Dalton, K. M., Coon, C. M., Greninger, P., Egan, R. K., Stein, G. T., Murchie, E., McClanaghan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111095 · Cited by 19
Osteochondroma in long‐term survivors of high‐risk neuroblastoma
Kushner, B. H., Roberts, S. S., Friedman, D. N., Kuk, D., Ostrovnaya, I., Modak, S. I., Kramer, K., Basu, E. M., & Cheung, N. V. (2015) · Cancer · doi:10.1002/cncr.29316 · Cited by 20
PI3King on MYCN to Improve Neuroblastoma Therapeutics
Hogarty, M. D., & Maris, J. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.018 · Cited by 19
“Though there have been recent impressive translational successes for this tumor, such as immunotherapy using an antibody targeting cell-surface GD2 given with immunostimulatory cytokines (Yu et al., 2010), 3 year relapse free survival estimates for high-risk disease remain under 50%.”
BackgroundSelf-citationLaQuaglia, M. P. (2013) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2013.11.029 · Cited by 19
Cerebral ganglioneuroblastoma of adult onset: Two patients and a review of the literature
Schipper, M. H., van Duinen, S. G., TAPHOORN, M. J. B., Kloet, A., Walchenbach, R., Wiggenraad, R. G. J., & Vecht, C. J. (2012) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2012.03.015 · Cited by 19
Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells
Sun, M. T., Ha, N., Pham, D.-H., Frederick, M. A., Sharma, B., Naruse, C., Asano, M., Pipkin, M. E., George, R. E., & Thai, T. (2017) · Scientific Reports · doi:10.1038/srep42888 · Cited by 20
New developments in immunotherapy for pediatric solid tumors
Schultz, L. M., Majzner, R. G., Davis, K. L., & Mackall, C. L. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000564 · Cited by 20
Tharakan, S., Raja, I., Pietraru, A., Sarecha, E., Gresita, A., Petcu, E., Ilyas, A., & Hadjiargyrou, M. (2023) · Gels · doi:10.3390/gels9040274 · Cited by 18
“GD2 is highly expressed in solid tumors, including osteosarcoma, and has been targeted prior as a treatment for neuroblastoma [43].”
BackgroundDodging the bullet: therapeutic resistance mechanisms in pediatric cancers
Shah, N. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.20 · Cited by 18
Li, C., Wang, S., & Yang, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117657 · Cited by 18
Retractedbub1 as a potential oncogene and a prognostic biomarker for neuroblastoma
Song, J., Ni, C., Dong, X., Sheng, C., Qu, Y., & Zhu, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.988415 · Cited by 22
“Despite significant advances in surgical treatment and immunotherapies and the wide clinical application of these interventions, cancer recurrence, metastasis, and cancer-related death are still frequently reported (13, 15, 39, 40).”
BackgroundHigh-Risk Neuroblastoma: A Surgical Perspective
Jacobson, J. C., Clark, R., & Chung, D. H. (2023) · Children · doi:10.3390/children10020388 · Cited by 18
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.